MedTrace Logo

Pirfenidone LP or Collagen-polyvinylpyrrolidone in COVID-19

NCT06585319 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-09-05

No results posted yet for this study

Summary

Collagen-polyvinylpyrrolidone (collagen-PVP) and pirfenidone have the ability to control cytokine storms. This work explores the therapeutic effects of both, on the early treatment of patients with severe COVID-19. The hospital stay, quick COVID-19 severity index (qCSI) and admission to the ICU were statistically significantly lower when the patients were treated with collagen-PVP or pirfenidone, compared to the controls treated with dexamethasone alone.

Conditions

  • COVID 19

Interventions

DRUG

Collagen-polyvinylpyrrolidone

2 ml intramuscular q24 h

DRUG

Pirfenidone 1200 mg

1,200 mg of oral q12 h

Sponsors & Collaborators

  • Materno-Perinatal Hospital of the State of Mexico

    lead OTHER

Principal Investigators

  • Hugo Mendieta Zerón, PhD · Mónica Pretelini Sáenz Maternal Perinatal Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-06-30
Completion
2024-08-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06585319 on ClinicalTrials.gov